Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Cardiovascular Medicine
Erschienen in: Current Treatment Options in Cardiovascular Medicine 2/2016

01.02.2016 | Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

In-Stent Restenosis: Pathophysiology and Treatment

verfasst von: Patrick M. Looser, MD, Luke K. Kim, MD, Dmitriy N. Feldman, MD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Opinion statement

Management of in-stent restenosis (ISR) remains a clinical challenge after both bare metal stent and drug-eluting stent placement. Autopsy studies and intravascular imaging have augmented our understanding of the pathophysiology of ISR. The clinical presentation and symptoms vary considerably among patients from stable angina to unstable angina and acute myocardial infarction. Potential treatment strategies include plain old balloon angioplasty (POBA), rotational atherectomy, vascular brachytherapy (VBT), bare metal stents (BMS), drug-coated balloons (DCBs), and drug-eluting stent (DES) placement. The most efficacious therapy depends on patient and lesion characteristics, but drug-eluting stents and drug-coated balloons yield the most successful angiographic and clinical results. Here, we discuss the underlying pathology, risk factors, and clinical presentation of ISR while examining the evidence supporting the optimal interventional techniques for this commonly encountered clinical entity.
Literatur
1.
Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897–907.CrossRefPubMed
2.
Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659–73.CrossRefPubMed
3.
Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, et al. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of subjects with de novo native coronary artery lesions trial. Am Heart J. 2013;166(6):1035–42.CrossRefPubMed
4.
Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8(6):e002230.CrossRefPubMed
5.
Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872–8.CrossRefPubMed
6.
Zhang BC, Karanasos A, Regar E. OCT demonstrating neoatherosclerosis as part of the continuous process of coronary artery disease. Herz. 2015;40(6):845–54.PubMedCentralCrossRefPubMed
7.
Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. 2004;109(9):1085–8.CrossRefPubMed
8.
Lee SW, Lee JY, Ahn JM, Park DW, Han S, Park YK, et al. Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials). Am J Cardiol. 2013;112(11):1738–44.CrossRefPubMed
9.
Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.CrossRef
10.
American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography and Interventions, Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–122.CrossRef
11.
Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57(11):1314–22.PubMedCentralCrossRefPubMed
12.
Tada T, Kadota K, Hosogi S, Miyake K, Ohya M, Amano H, et al. Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation. Eur Heart J Cardiovasc Imaging. 2015;16(10):1101–11.CrossRefPubMed
13.
Jang JY, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, et al. Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis. Atherosclerosis. 2015;242(2):553–9.CrossRefPubMed
14.
Goto K, Zhao Z, Matsumura M, Dohi T, Kobayashi N, Kirtane AJ, Rabbani LE, Collins MB, Parikh MA, Kodali SK, Leon MB, Moses JW, Mintz GS, Maehara A. Mechanisms and patterns of intravascular ultrasound in-stent restenosis among bare metal stents and first- and second-generation drug-eluting stents. Am J Cardiol. 2015.
15.
Wakabayashi K, Mintz G, Delhaye C, Choi YJ, Doh JH, Ben-Dor I, et al. In vivo virtual histology intravascular ultrasound comparison of neointimal hyperplasia within drug-eluting- versus bare metal stents. J Invasive Cardiol. 2011;23(7):262–8.PubMed
16.
Tocci G, Barbato E, Coluccia R, Modestino A, Pagliaro B, Mastromarino V, Giovannelli F, Berni A, Volpe M. Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis. Am J Hypertens. 2015.
17.
Zhao LP, Xu WT, Wang L, Li H, Shao CL, Gu HB, et al. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up. Coron Artery Dis. 2015;26(1):5–10.CrossRefPubMed
18.
Magalhaes MA, Minha S, Chen F, Torguson R, Omar AF, Loh JP, et al. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. Circ Cardiovasc Interv. 2014;7(6):768–76.CrossRefPubMed
19.
Rathore S, Kinoshita Y, Terashima M, Katoh O, Matsuo H, Tanaka N, et al. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. Euro Interv. 2010;5(7):841–6.
20.
Nam CW, Rha SW, Koo BK, Doh JH, Chung WY, Yoon MH, et al. Usefulness of coronary pressure measurement for functional evaluation of drug-eluting stent restenosis. Am J Cardiol. 2011;107(12):1783–6.CrossRefPubMed
21.
Park SJ, Kim KH, Oh IY, Shin DH, Park KI, Seo MK, et al. Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents. Circ J. 2010;74(9):1837–45.CrossRefPubMed
22.
Song HG, Park DW, Kim YH, Ahn JM, Kim WJ, Lee JY, et al. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. J Am Coll Cardiol. 2012;59(12):1093–100.CrossRefPubMed
23.
Takano M, Yamamoto M, Murakami D, et al. Optical coherence tomography after new scoring balloon angioplasty for in-stent restenosis and de novo coronary lesions. Int J Cardiol. 2010;141:e51–3.CrossRefPubMed
24.
Singh GD, Armstrong EJ, Laird JR. Femoropopliteal in-stent restenosis: current treatment strategies. J Cardiovasc Surg (Torino). 2014;55(3):325–33.
25.
Byrne R. Intracoronary stenting and angiographic results: optimizing treatment of drug eluting stent in-stent restenosis 4—ISAR-DESIRE 4. Presented at TCT 2015, San Francisco.
26.
O’Brien ER, Glover C, Labinaz M. Acute outcome with the flexicut directional coronary atherectomy catheter for the treatment of coronary in-stent restenosis. J Invasive Cardiol. 2001;13(9):618–22.PubMed
27.
vom Dahl J, Dietz U, Haager PK, Silber S, Niccoli L, Buettner HJ, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation. 2002;105(5):583–8.CrossRef
28.
Alfonso F, Sandoval J, Nolte C. Calcified in-stent restenosis: a rare cause of dilation failure requiring rotational atherectomy. Circ Cardiovasc Interv. 2012;5(1):e1–2.CrossRefPubMed
29.
Oliver LN, Buttner PG, Hobson H, Golledge J. A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in- stent restenosis. Int J Cardiol. 2008;126:216–23.PubMedCentralCrossRefPubMed
30.
Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet. 2002;359:551–7.CrossRefPubMed
31.
Alli OO, Teirstein PS, Satler L, Sketch Jr MH, Popma JJ, Mauri L, et al. Five-year follow-up of the sirolimus-eluting stents vs vascular brachytherapy for bare metal in-stent restenosis (SISR) trial. Am Heart J. 2012;163(3):438–45.CrossRefPubMed
32.
Benjo A, Cardoso RN, Collins T, Garcia D, Macedo FY, El-Hayek G, et al. Vascular brachytherapy versus drug-eluting stents in the treatment of in-stent restenosis: a meta-analysis of long-term outcomes. Catheter Cardiovasc Interv. 2015. doi:10.​1002/​ccd.​25998.
33.
Mintz GS, Hoffmann R, Mehran R, Pichard AD, Kent KM, Satler LF, et al. In-stent restenosis: the Washington Hospital Center experience. Am J Cardiol. 1998;81(7A):7E–13.CrossRefPubMed
34.
Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, López-Minguez JR, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol. 2003;42(5):796–805.CrossRefPubMed
35.
Alfonso F, Augé JM, Zueco J, Bethencourt A, López-Mínguez JR, Hernández JM, et al. Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol. 2005;46(5):756–60.CrossRefPubMed
36.
Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Fernandez C, Escaned J, Bañuelos C, et al. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: results of a pooled analysis of two randomized studies. Catheter Cardiovasc Interv. 2008;72(4):459–67.CrossRefPubMed
37.
Alfonso F, Pérez-Vizcayno MJ, Hernández R, Bethencourt A, Martí V, López-Mínguez JR, et al. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol. 2008;52(20):1621–7.CrossRefPubMed
38.
Samady H, Mekonnen G. Drug-eluting balloons: effective and durable treatment for in-stent restenosis. JACC Cardiovasc Interv. 2013;6(6):577–9.CrossRefPubMed
39.
Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355(20):2113–24.CrossRefPubMed
40.
Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986–94.CrossRefPubMed
41.
Indermuehle A, Bahl R, Lansky AJ, Froehlich GM, Knapp G, Timmis A, et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart. 2013;99(5):327–33.CrossRefPubMed
42.•
Xu B, Gao R, Wang J, Yang Y, Chen S, Liu B, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014;7(2):204–11. Large randomized trial comparing DCB and 1st generation stents.CrossRefPubMed
43.
Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381(9865):461–7.CrossRefPubMed
44.
Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Schüpke S, Hoppmann P, et al. Long-term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis: 3-year results of a randomized controlled trial. JACC Cardiovasc Interv. 2015;8(7):877–84.CrossRefPubMed
45.
Habara S, Kadota K, Shimada T, Ohya M, Amano H, Izawa Y, et al. Late restenosis after paclitaxel-coated balloon angioplasty occurs in patients with drug-eluting stent restenosis. J Am Coll Cardiol. 2015;66(1):14–22.CrossRefPubMed
46.
Scheller B, Fontaine T, Mangner N, Hoffmann S, Bonaventura K, Clever YP, et al. A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: results from the multi-center randomized controlled PATENT-C first in human trial. Catheter Cardiovasc Interv. 2015. doi:10.​1002/​ccd.​26216.PubMed
47.•
Miglionico M, Mangiacapra F, Nusca A, Scordino D, Gallo P, Campanale M, Melfi R, Di Sciascio G. Efficacy and safety of paclitaxel-coated balloon estenosis in high-risk patients. Am J Cardiol. 2015. Important paper documenting DCB use in high risk patients.
48.
Kawamoto H, Ruparelia N, Latib A, Miyazaki T, Sato K, Mangieri A, et al. Drug-coated balloons versus second-generation drug-eluting stents for the management of recurrent multimetal-layered in-stent restenosis. JACC Cardiovasc Interv. 2015;8(12):1586–94.CrossRefPubMed
49.
Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293(2):165–71.CrossRefPubMed
50.
Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Bethencourt A, Martí V, López-Mínguez JR, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol. 2006;47(11):2152–60.CrossRefPubMed
51.•
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García del Blanco B, García-Touchard A, López-Minguéz JR, et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV Randomized Clinical Trial. J Am Coll Cardiol. 2015;66(1):23–33. Largest randomized trial comparing EES and DEB in patients with DES-ISR.CrossRefPubMed
52.•
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014;63(14):1378–86. Largest randomized trial comparing EES and DEB in patients with BMS-ISR.CrossRefPubMed
53.•
Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, et al. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv. 2015;8(3):382–94. Large meta-analysis examining clinical outcomes in patients with ISR.CrossRefPubMed
54.•
Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386(9994):655–64. Large meta-analysis comparing angiographic results of numerous treatment strategies.CrossRefPubMed
55.
Alfonso F, Nuccio J, Cuevas C, Cárdenas A, Gonzalo N, Jimenez-Quevedo P. Treatment of coronary in-stent restenosis with bioabsorbable vascular scaffolds. J Am Coll Cardiol. 2014;63(25 Pt A):2875.CrossRefPubMed
56.
Deora S, Shah S, Pancholy S, Patel T. Bioresorbable vascular scaffold for coronary in-stent restenosis: a novel concept. Indian Heart J. 2014;66(4):459–61.PubMedCentralCrossRefPubMed
57.
Pereira-da-Silva T, Patrício L, Cruz Ferreira R. Rotational atherectomy combined with bioresorbable vascular scaffold implantation: a feasible approach for recurrent in-stent restenosis when other therapies failed. J Invasive Cardiol. 2015;27(7):E143–5.PubMed
58.
Metadaten
Titel
In-Stent Restenosis: Pathophysiology and Treatment
verfasst von
Patrick M. Looser, MD
Luke K. Kim, MD
Dmitriy N. Feldman, MD
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 2/2016
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-015-0433-7

Weitere Artikel der Ausgabe 2/2016

Current Treatment Options in Cardiovascular Medicine 2/2016 Zur Ausgabe

Heart Failure (W Tang, Section Editor)

Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Management of Coronary Artery Disease and Conduction Abnormalities in Transcatheter Aortic Valve Implantation

Arrhythmia (D Spragg, Section Editor)

The Emerging Roles of Leadless Devices

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Glycemic Control in Coronary Revascularization

Heart Failure (W Tang, Section Editor)

Desensitization Strategies Pre- and Post-Cardiac Transplantation

Heart Failure (W Tang, Section Editor)

Management of Cardio-Renal Syndrome and Diuretic Resistance

Neu im Fachgebiet Kardiologie

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Shunt-Therapie bei Herzinsuffizienz: Kein Anzug, der allen passt

13.05.2024 Chronische Herzinsuffizienz Nachrichten

Die Anlage eines interatrialen Shunts zur Reduktion des linksatrialen Drucks ist ein neuer Therapieansatz bei Herzinsuffizienz. Viele Patienten sprechen darauf an, andere jedoch nicht. 

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise